GB201019525D0 - Oil-based formulations - Google Patents
Oil-based formulationsInfo
- Publication number
- GB201019525D0 GB201019525D0 GB201019525A GB201019525A GB201019525D0 GB 201019525 D0 GB201019525 D0 GB 201019525D0 GB 201019525 A GB201019525 A GB 201019525A GB 201019525 A GB201019525 A GB 201019525A GB 201019525 D0 GB201019525 D0 GB 201019525D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- prodrug
- gut lumen
- oil
- premature
- premature hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the use of oil based delivery vehicles to prevent undesirable premature hydrolysis of phenolic amino benzoic acid carbamate prodrugs, while resident in the gut lumen. Preclusion of water and hydrolytic enzymes prior to prodrug absorption ensures that such compounds can be fully absorbed intact without undergoing unintended premature hydrolysis in the gastrointestinal tract so maximizing the benefit of improved systemic availability afforded by the prodrug. Furthermore judicious selection of oil and prodrug salt form can result in a sustained release plasma PK profile. The avoidance of premature degradation and release of active drug into the gut lumen minimizes any potential for a direct adverse interaction within the gut lumen.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201019525A GB201019525D0 (en) | 2010-11-18 | 2010-11-18 | Oil-based formulations |
PCT/GB2011/052262 WO2012066347A1 (en) | 2010-11-18 | 2011-11-18 | Oil based formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201019525A GB201019525D0 (en) | 2010-11-18 | 2010-11-18 | Oil-based formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201019525D0 true GB201019525D0 (en) | 2010-12-29 |
Family
ID=43431636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201019525A Ceased GB201019525D0 (en) | 2010-11-18 | 2010-11-18 | Oil-based formulations |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201019525D0 (en) |
WO (1) | WO2012066347A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019007441A1 (en) * | 2017-07-04 | 2019-01-10 | 山东丹红制药有限公司 | Sustained release suspension containing dezocine analogue ester and preparation method therefor |
EP3946547A4 (en) * | 2019-03-26 | 2023-01-18 | Pocket Naloxone Corp. | Devices and methods for delivering pharmaceutical compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8628796B2 (en) * | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
US9056050B2 (en) * | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
RU2012106605A (en) * | 2009-07-23 | 2013-08-27 | ШАЙЕ ЭлЭлСи | AMINO ACID AND PEPTIDE MEDICINES OF HALANTAMINE AND THEIR APPLICATION |
WO2011133151A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof |
-
2010
- 2010-11-18 GB GB201019525A patent/GB201019525D0/en not_active Ceased
-
2011
- 2011-11-18 WO PCT/GB2011/052262 patent/WO2012066347A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012066347A1 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259334A (en) | Biodegradable lipids for the delivery of active agents | |
IL208260A0 (en) | Nanoparticles for targeted delivery of active agents to the lung | |
WO2011163594A3 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
WO2011012816A3 (en) | Pharmaceutical formulation | |
IL222548A (en) | Hydroxamic acid derivatives and pharmaceutical compositions and antimicrobial agents comprising the same | |
WO2011051354A3 (en) | Transdermal pharmaceutical compositions comprising active agents | |
EP2419138A4 (en) | Gel compositions for administration of pharmaceutically active compounds | |
NZ592647A (en) | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester | |
EP3677261B8 (en) | Administration of serine protease inhibitors to the stomach | |
WO2011142731A3 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
WO2012040331A3 (en) | Multistage nanoparticles | |
IL205313A0 (en) | Pharmaceutical formulation of clavulanic acid | |
WO2011129579A3 (en) | Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent | |
WO2012064302A3 (en) | Improved montelukast formulations | |
GB201019525D0 (en) | Oil-based formulations | |
WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
WO2013068960A3 (en) | Monounsaturated fatty acid for nailcare | |
MX346316B (en) | Pharmaceutical or neutraceutical formulation. | |
PL2585041T3 (en) | Taste-masked pharmaceutical formulation having accelerated onset of action | |
MX2015006011A (en) | Medicinal lozenge based on ibuprofen sodium dihydrate. | |
WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
EP2175862A4 (en) | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds | |
WO2012064306A3 (en) | Effervescent formulations of rosuvastatin | |
WO2011152805A3 (en) | Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |